Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cd45 and Cd52 Monoclonal Antibody Conditioning Regimen for Stem Cell Transplant in Fanconi Anemia
NCT00590460Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2001
- Primary completion
- Sep 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YTH25.4 + YTH54.12 and alemtuzumab in Fanconi anemia (FA), aplastic anemia, dyskeratosis congenita (DC) and 1 more, sponsored by Baylor College of Medicine. Primary endpoint: Number of Patients With Donor Engraftment at 100 days. Started Jul 2001; status: terminated.
02
Drugs
YTH25.4 + YTH54.12alemtuzumab
03
Conditions
Fanconi anemia (FA)aplastic anemiadyskeratosis congenita (DC)Nijmegen breakage syndrome (NBS)
Beyond the preview
Go deeper on NCT00590460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590460.